EBS Stock Analysis: Buy, Sell, or Hold?
EBS - Emergent Biosolutions, Inc.
$6.10
0.19 (3.21%)
â˛
5d:
+17.76%
30d:
-15.51%
90d:
-28.15%
WAIT
LOW Confidence
Analysis Updated: Aug 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When EBS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: EBS is fairly priced but lacks strong directional signals. At -23.5% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: EBS is fairly priced but lacks strong directional signals. At -23.5% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$26.49
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$16.45
62.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EBS is currently trading at $6.10, which is considered fair relative to its 30-day fair value range of $4.80 to $7.33. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.8) compared to its historical average (13.0). Remarkably, the market is currently pricing in an annual earnings decline of 23.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, EBS is in a strong downtrend. The price is approaching resistance at $6.12. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $11.00 (+80.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EBS is in a strong downtrend. The price is approaching resistance at $6.12. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $11.00 (+80.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$4.80 -
$7.33
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.1%
Protect Your Profits
Holding EBS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.2%)
- BULLISH: Trading 80.3% below Wall St target ($11.00)
- WARNING: Composite score 44/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.80 -
$7.33
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$4.46
Resistance Level
$6.12
Current Trend
Strong Downtrend
Technical data as of
Aug 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.83
Wall Street Target
$11.00
(+80.3%)
Revenue Growth (YoY)
66.3%
Earnings Growth (YoY)
-93.8%
Profit Margin
-23.0%
Valuation Discount vs History
-23.5% cheaper
PE vs Historical
5.8 vs 13.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-23.5%
(market-implied from PE analysis)
1-Year Target
$5.49
(-10%)
2-Year Target
$4.94
(-19%)
3-Year Target
$4.45
(-27%)
3-Yr Target (if PE normalizes)
(PE: 6â13)
$9.92
(+63%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 191.0%)
$70.99
(+1064%)
Base:
(SPY PE: 5.8, Growth: 191.0%)
$20.59
(+238%)
Bear:
(PE: 5.0, Growth: 191.0%)
$17.50
(+187%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.8 to 13.0
Stabilization Target:
$13.60
(+123.0%)
PE Expansion Potential:
+123.0%
Share & Embed Analysis
Last updated: August 31, 2026 7:44 PM ET
Data refreshes hourly during market hours. Next update: 8:44 PM
Data refreshes hourly during market hours. Next update: 8:44 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EBS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$212 | 70 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 53 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 65 BUY |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 41 HOLD |
Advanced EBS Option Strategies
Professional options setups generated by AI based on today's EBS price and gamma walls.
